DBV Technologies S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of June 2019, specifically dated June 3, 2019. DBV Technologies S.A. is a clinical-stage biopharmaceutical company headquartered in Montrouge, France, with additional offices in New York, NY. The company focuses on developing Viaskin, a proprietary epicutaneous immunotherapy (EPIT) platform designed to treat food allergies and other immune diseases.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a press release regarding corporate events and does not contain financial statements or quantitative financial data.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document serves as an announcement of upcoming management presentations rather than a financial update.
Guidance, Outlook, and Management Commentary
Management has scheduled presentations at three major investor conferences in June 2019 to discuss the company's progress:
- Jefferies 2019 Global Healthcare Conference: Kevin Trapp, Chief Commercial Officer, presenting on June 7, 2019.
- Goldman Sachs 40th Annual Global Healthcare Conference: Daniel Tassé, Chief Executive Officer, presenting on June 12, 2019.
- JMP Securities Life Sciences Conference: Daniel Tassé, Chief Executive Officer, presenting on June 19, 2019.
Live webcasts and replays of these events are available on the company's investor relations website. The company continues ongoing clinical trials for Viaskin Peanut and Viaskin Milk, preclinical development of Viaskin Egg, and a human proof-of-concept study for Viaskin Milk in treating Eosinophilic Esophagitis.
Key Facts for Investor Verification
- Verify the dates and times of the upcoming investor conference presentations listed above.
- Confirm the availability of live webcasts and replays via the company's official investor relations portal.
- Note that this filing contains no financial data; investors should refer to the most recent Form 20-F or quarterly reports for financial metrics.
- Review the status of clinical trials for Viaskin Peanut, Viaskin Milk, and Viaskin Egg in subsequent regulatory filings.